Symbiotec Pharmalab is a research-driven pharmaceutical and biotechnology company and a key player in corticosteroid and steroidal-hormone APIs, with FDA and EU-GMP approved manufacturing facilities.
GMP is an unofficial, unregulated grey-market indicator — not recognised by SEBI, NSE or BSE, and it can change quickly. Don't treat it as a guaranteed listing price.
| Issue Size | ₹1,757 crore |
|---|---|
| Price Band | ₹938 – ₹988 |
| Lot Size | 15 shares |
| Open Date | 2026-08-24 |
| Close Date | 2026-08-27 |
| Allotment Date | 2026-08-28 |
| Listing Date | 2026-09-01 |
| Registrar | MUFG Intime India |
| Date | GMP | Implied Premium |
|---|---|---|
| 2026-08-24 | ₹409 | +41.4% |
| 2026-08-20 | ₹320 | +32% |
Symbiotec Pharmalab opens for subscription on August 24, 2026 and closes August 27, 2026.
The price band is ₹938 to ₹988 per share, valuing the company at about ₹6,244 crore at the upper end.
MUFG Intime India (the renamed Link Intime) is the registrar.
Symbiotec Pharmalab opened for subscription today, August 24, with grey market premium already strong at around ₹409 — a 41.4% implied premium over the ₹988 upper price band.
Last updated 2026-08-24T07:20:00+05:30 · See what else is trending · Full IPO List